Beone Medicines
Clinical trials sponsored by Beone Medicines, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise for rare blood cancer Results expected Sep 2026 (estimated)
- Healthy volunteers to test new version of cancer drug Results expected Sep 2026 (estimated)
- Healthy volunteers needed to test drug interactions Results expected Sep 2026 (estimated)
- New hope for multiple myeloma: sonrotoclax trial targets resistant cancer Results expected Nov 2026 (estimated)
- New pill combo aims to improve leukemia control without chemo Results expected Nov 2026 (estimated)
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control Stopped earlyThis early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while als…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New pill targets common cancer mutation in early trial
Disease control Stopped earlyThis early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental lung cancer drug shows promise but trial halted early
Disease control Stopped earlyThis early-stage trial tested an experimental drug called BG-60366 in 33 people with advanced EGFR-mutant non-small cell lung cancer. The drug is designed to break down the faulty EGFR protein that drives cancer growth. The study aimed to check safety and find the right dose, but…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control Stopped earlyThis early-phase study tested a new oral drug called BG-89894 (SYH2039) in 29 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals were to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. The tri…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis study tested a new experimental drug called BGB-R046, given alone or with another drug (tislelizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminat…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC